Product Description
For the treatment of patients with mild to moderate COVID-19 (Sourced from: https://pubmed.ncbi.nlm.nih.gov/35044238/)
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Reperfusion Injury|Liver Transplant *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: Revive
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Arthritis, Rheumatoid
Phase 3: COVID-19
Phase 2: Cystinuria|Gout